Infinity Pharmaceuticals Company Profile (NASDAQ:INFI)

About Infinity Pharmaceuticals

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INFI
  • CUSIP: 45665G30
Key Metrics:
  • Previous Close: $2.28
  • 50 Day Moving Average: $2.10
  • 200 Day Moving Average: $1.57
  • 52-Week Range: $0.84 - $6.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.66
  • P/E Growth: -0.04
  • Market Cap: $114.87M
  • Outstanding Shares: 49,729,000
  • Beta: 2.55
Profitability:
  • Net Margins: 13.23%
  • Return on Equity: -125.20%
  • Return on Assets: -54.94%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 4.77%
  • Quick Ratio: 4.77%
Additional Links:
Companies Related to Infinity Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Infinity Pharmaceuticals (NASDAQ:INFI) (?)
Ratings Breakdown: 9 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $5.00 (116.45% upside)

Analysts' Ratings History for Infinity Pharmaceuticals (NASDAQ:INFI)
Show:
DateFirmActionRatingPrice TargetDetails
11/10/2016J P Morgan Chase & CoReiterated RatingHoldView Rating Details
8/11/2016Morgan StanleyReiterated RatingHold$1.00View Rating Details
8/10/2016FBR & CoReiterated RatingHoldView Rating Details
8/9/2016WedbushReiterated RatingNeutral$1.25 -> $1.00View Rating Details
6/15/2016Jefferies Group LLCDowngradeBuy -> HoldView Rating Details
6/15/2016William BlairDowngradeOutperform -> Market Perform$20.00 -> $2.00View Rating Details
6/15/2016Wells Fargo & CoDowngradeOutperform -> Market PerformView Rating Details
6/14/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$12.00 -> $2.00View Rating Details
6/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details
5/10/2015NomuraReiterated RatingNeutral -> Buy$17.00 -> $13.00View Rating Details
5/6/2015Deutsche Bank AGInitiated CoverageBuy$20.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
11/9/2016Q316($0.86)($0.39)$6.23 millionViewListenView Earnings Details
8/9/2016Q216($0.89)$1.05$13.91 million$9.47 millionViewListenView Earnings Details
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details
11/5/2015Q315($0.63)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details
5/6/2015Q115($1.68)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details
2/24/2015Q414($0.98)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details
11/6/2014Q314$0.30$2.03$141.40 million$160.60 millionViewListenView Earnings Details
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details
5/6/2014Q1($0.83)($0.87)ViewListenView Earnings Details
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)
Current Year EPS Consensus Estimate: $-0.71 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.91)($0.79)($0.85)
Q2 20164($1.02)($0.83)($0.92)
Q3 20164($0.93)($0.76)($0.87)
Q4 20164($1.04)($0.39)($0.75)
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.12)($0.12)($0.12)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Infinity Pharmaceuticals (NASDAQ:INFI)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 79.56%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Value Fund L P BiotechnologyMajor ShareholderBuy4,379$1.34$5,867.86View SEC Filing  
12/30/2016Value Fund L P BiotechnologyMajor ShareholderBuy742,401$1.34$994,817.34View SEC Filing  
12/20/2016Value Fund L P BiotechnologyMajor ShareholderBuy654,921$1.31$857,946.51View SEC Filing  
12/13/2016Sujay KangoInsiderSell75,000$1.28$96,000.00View SEC Filing  
12/12/2016Sujay KangoInsiderSell25,009$1.30$32,511.70View SEC Filing  
12/2/2016Value Fund L P BiotechnologyMajor ShareholderBuy201,394$1.19$239,658.86View SEC Filing  
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00View SEC Filing  
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Infinity Pharmaceuticals (NASDAQ:INFI)
DateHeadline
News IconTrading Sheet: Examining the Levels for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Baldwin Journal (NASDAQ:INFI)
baldwinjournal.com - February 25 at 12:12 AM
News IconWhat are Brokerage Firms Saying About Infinity Pharmaceuticals ... - Aiken Advocate (NASDAQ:INFI)
aikenadvocate.com - February 25 at 12:12 AM
News IconInsider Buying: Infinity Pharmaceuticals, Inc. (INFI) Major Shareholder Buys $994817.34 in Stock - Petro Global News 24 (NASDAQ:INFI)
petroglobalnews24.com - February 24 at 10:16 AM
News IconWall Street Consensus Watch on Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Rockville Register (NASDAQ:INFI)
rockvilleregister.com - February 20 at 10:36 AM
openpr.com logoDiffuse Large B-Cell Lymphoma Market - Detailed Analysis and Forecast by 2025 (NASDAQ:INFI)
www.openpr.com - February 17 at 5:30 PM
News IconInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Bearish Target At $2 - Stock Observer (NASDAQ:INFI)
www.thestockobserver.com - February 16 at 8:10 AM
4-traders.com logoInfinity Pharmaceuticals : Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer (NASDAQ:INFI)
www.4-traders.com - February 15 at 12:20 AM
streetinsider.com logoInfinity Pharma (INFI) Names Jeffery Kutok to CSO (NASDAQ:INFI)
www.streetinsider.com - February 14 at 12:01 AM
us.rd.yahoo.com logoInfinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer (NASDAQ:INFI)
us.rd.yahoo.com - February 13 at 11:12 AM
us.rd.yahoo.com logo8:36 am Infinity Pharmaceutical announces that Jeffery Kutok has been promoted to the role of Chief Scientific Officer effective immediately (NASDAQ:INFI)
us.rd.yahoo.com - February 13 at 11:12 AM
News IconQuarterly EPS Of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Set At $-0.24 - Stock Observer (NASDAQ:INFI)
www.thestockobserver.com - February 12 at 4:03 AM
News IconInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Daily Sentiment Score At 0.268 - Stock Observer (NASDAQ:INFI)
www.thestockobserver.com - February 6 at 10:59 PM
News IconStock Trickling Lower Heading Into The Open: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Aiken Advocate (NASDAQ:INFI)
aikenadvocate.com - February 6 at 5:58 PM
News IconStock Roaring Upward Mid-Session: Infinity Pharmaceuticals, Inc ... - Aiken Advocate (NASDAQ:INFI)
aikenadvocate.com - February 6 at 5:58 PM
prnewswire.com logoInfinity to Present at the 2017 BIO CEO & Investor Conference - PR Newswire (press release) (NASDAQ:INFI)
www.prnewswire.com - February 6 at 5:58 PM
finance.yahoo.com logoInfinity to Present at the 2017 BIO CEO & Investor Conference (NASDAQ:INFI)
finance.yahoo.com - February 6 at 10:35 AM
News IconMy Watchlist for Thursday, February 02 (NASDAQ:INFI)
ac-investor.blogspot.com - February 1 at 11:43 PM
News IconStock Carving Out Mid-Session Gains For Traders: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Wall Street Beacon (NASDAQ:INFI)
wsbeacon.com - February 1 at 6:41 PM
News IconStock Vacillating as Volatility Hits a High Point For Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Wall Street Beacon (NASDAQ:INFI)
wsbeacon.com - January 31 at 6:40 PM
News IconCalling all Bargain Hunters: Stock Update on Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Prospect Journal (NASDAQ:INFI)
prospectjournal.com - January 30 at 6:37 PM
News IconIs This Stock Capable of a Bull Run: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Nelson Research (NASDAQ:INFI)
nelsonobserver.com - January 30 at 10:45 AM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Jazz Pharma, Infinity Pharma, Acorda Therapeutics, and Ultragenyx ... - PR Newswire (press release) (NASDAQ:INFI)
www.prnewswire.com - January 30 at 10:45 AM
News IconQuarterly EPS Of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Set At ... - Stock Observer (NASDAQ:INFI)
www.thestockobserver.com - January 28 at 6:04 PM
istreetwire.com logoThree Movers to Watch for: Infinity Pharmaceuticals, Inc. (INFI), Hope Bancorp, Inc. (HOPE), Keryx ... - iStreetWire (NASDAQ:INFI)
istreetwire.com - January 27 at 7:52 PM
News IconAnalysts Sentiment on Lam Research Corporation (LRCX) (NASDAQ:INFI)
vgtoday.net - January 27 at 12:40 AM
News IconInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Analysts Recommendations and Insider Trading (NASDAQ:INFI)
flapship.com - January 25 at 4:44 AM
News IconInfinity Pharmaceuticals, Inc. (INFI) Stock Price Increases 33.33% - Highland Mirror (NASDAQ:INFI)
www.highlandmirror.com - January 24 at 6:41 PM
News IconEarnings in Full Force, Analysts Take Aim at Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Wall Street Beacon (NASDAQ:INFI)
wsbeacon.com - January 24 at 6:41 PM
News IconTraders Alert: Gulfport Energy Corp. (NASDAQ:GPOR), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - The Newburgh Press (NASDAQ:INFI)
newburghpress.com - January 23 at 6:12 PM
News IconPriming The Pump: Stock Volatility Spotted in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Wall Street Beacon (NASDAQ:INFI)
wsbeacon.com - January 23 at 6:12 PM
News IconInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:INFI)
www.thestockobserver.com - January 23 at 10:49 AM
News IconBoom or Bust? Is there any value in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Prospect Journal (NASDAQ:INFI)
prospectjournal.com - January 23 at 10:49 AM
News IconMy Watchlist for Monday, January 23 (NASDAQ:INFI)
ac-investor.blogspot.com - January 22 at 5:46 PM
4-traders.com logoInfinity Pharmaceuticals : Presents Preclinical Data and Phase 1 Clinical Data on IPI-549 at PI3K Keystone Symposia Conference (NASDAQ:INFI)
www.4-traders.com - January 20 at 9:05 PM
us.rd.yahoo.com logoInfinity Presents Preclinical Data and Phase 1 Clinical Data on IPI-549 at PI3K Keystone Symposia Conference (NASDAQ:INFI)
us.rd.yahoo.com - January 20 at 9:05 PM
istreetwire.com logoEye Catching Stocks: Radian Group Inc. (RDN), Infinity ... - istreetwire - iStreetWire (NASDAQ:INFI)
istreetwire.com - January 20 at 3:29 PM
News IconAnalysts Take the Wheel on Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:INFI)
aikenadvocate.com - January 20 at 3:29 PM
4-traders.com logoVerastem : Announces Executive Leadership Appointments and Changes (NASDAQ:INFI)
www.4-traders.com - January 20 at 12:43 AM
News IconDecibel Therapeutics Expands Leadership Team With World-Class Bioinformatics Scientist; Appoints Three New Members to its Board of Directors (NASDAQ:INFI)
www.cbs58.com - January 18 at 11:27 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Wall Street Beacon (NASDAQ:INFI)
wsbeacon.com - January 18 at 6:25 PM
News IconStock Mounting Higher in Afternoon Session: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Wall Street Beacon (NASDAQ:INFI)
wsbeacon.com - January 18 at 4:06 AM
News IconMy Watchlist for Wednesday, January 18 (NASDAQ:INFI)
ac-investor.blogspot.com - January 17 at 6:05 PM
News IconKnuckling Down on Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Prospect Journal (NASDAQ:INFI)
prospectjournal.com - January 17 at 1:04 PM
News IconWill The Needle Move For Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:INFI)
wsbeacon.com - January 17 at 1:04 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Infinity ... - Wall Street Beacon (NASDAQ:INFI)
wsbeacon.com - January 16 at 5:55 PM
News IconIs There Any Upside to This Stock Under $5: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Prospect Journal (NASDAQ:INFI)
prospectjournal.com - January 16 at 5:55 PM
seekingalpha.com logoInfinity Pharmaceuticals (INFI) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:INFI)
seekingalpha.com - January 13 at 7:10 PM
News IconInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Daily Sentiment Score At 0.56 - Stock Observer (NASDAQ:INFI)
www.thestockobserver.com - January 11 at 8:00 AM
News IconPlacing This Stock in the Hotbed: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) - Prospect Journal (NASDAQ:INFI)
prospectjournal.com - January 11 at 8:00 AM
tmcnet.com logoJulian Adams, Ph.D. Joins Vedantra Pharmaceuticals as Executive Chairman (NASDAQ:INFI)
www.tmcnet.com - January 9 at 6:37 PM

Social

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Where is Infinity Pharmaceuticals' stock going? Where will Infinity Pharmaceuticals' stock price be in 2017?

9 equities research analysts have issued 12-month target prices for Infinity Pharmaceuticals' shares. Their forecasts range from $1.00 to $17.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $5.00 in the next year.

When will Infinity Pharmaceuticals announce their earnings?

Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Infinity Pharmaceuticals stock?

Here are some recent quotes from research analysts about Infinity Pharmaceuticals stock:

  • According to Zacks Investment Research, "Infinity, a development-stage biopharmaceutical company, is focused on the development of treatments for difficult-to-treat diseases. Estimates have been mostly stable ahead of the company’s Q3 earnings release. Infinity received a huge blow when AbbVie decided to terminate the collaboration for the development and commercialization of Infinity’s lead pipeline candidate, duvelisib. With the termination of this agreement, Infinity has regained the global rights to the candidate. Currently, the company is exploring strategic options for the duvelisib program, including a potential sale of the same. Therefore, the company has refrained from giving an update on the nature and timing of regulatory filing of the candidate. Infinity also announced restructuring plans and cut approximately 66% of its workforce. Infinity is also moving with its planned development of other immuno-oncology candidate IPI-549 in multiple solid tumors." (10/18/2016)

  • J P Morgan Chase & Co analysts commented, "Top-line pivotal data from phase 2 DYNAMO trial of duvelisib in refractory iNHL are expected early-3Q and is a key catalyst for Infinity this year (enabling a potential accelerated approval filing by YE16). While iNHL remains competitive among approved and developing therapeutics, based on physician feedback, we believe duvelisib has multiple potential shots at differentiation with respect to both the efficacy and / or safety profile. On efficacy, our physician feedback indicates that an overall response rate (ORR) of 65%+, particularly if driven by complete responses (CRs; 20%+) would be highly differentiated. Additionally, potential points of differentiation on the safety side include a lower overall rate of discontinuation, as well as lower rates of individual AEs such abnormal liver enzymes and diarrhea. Related to INFI shares heading into the DYNAMO readout, we believe the reward / risk is very favorable. Indeed, we see upside in INFI shares of 100-140% on efficacy and / or safety differentiation and downside of 25-30% (which is essentially cash, with no differentiation of the efficacy or safety side). We are adjusting our price target to $10 from prior $13 after taking a more conservative approach to the duvelisib model. Reiterate Overweight rating on INFI shares." (3/31/2016)

Who owns Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (6.54%), Renaissance Technologies LLC (3.42%), Pinnacle Associates Ltd. (2.69%), FMR LLC (2.39%), State Street Corp (1.99%) and Numeric Investors LLC (1.57%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Sujay Kango, Value Fund L P Biotechnology and Vito J Palombella.

Who sold Infinity Pharmaceuticals stock? Who is selling Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bogle Investment Management L P DE, State Street Corp and Pinnacle Associates Ltd..

Who bought Infinity Pharmaceuticals stock? Who is buying Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Tudor Investment Corp Et Al, Oxford Asset Management, FMR LLC and Numeric Investors LLC.

How do I buy Infinity Pharmaceuticals stock?

Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Infinity Pharmaceuticals stock cost?

One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $2.31.

Infinity Pharmaceuticals (NASDAQ:INFI) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Earnings History Chart

Earnings by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Dividend History Chart

Dividend Payments by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Last Updated on 2/25/2017 by MarketBeat.com Staff